AlphaMadera's AlphaVal page computes Rh's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag RH as undervalued, fairly valued, or overvalued.

What is Rh's fair value?

Fair value for RH is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value RH?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from RH's most recent reported fundamentals.

RH - Rh

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $167.50 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Mild

Trading 0.3% above fair value

Current Price $165.35

Bear Case $144.22 12.8% downside ($144.22 - $165.35) / $165.35 = -12.8% $10.23 × 14x P/E

Fair Value $164.83 0.3% downside ($164.83 - $165.35) / $165.35 = -0.3% $10.23 × 16x P/E

Bull Case $185.43 12.1% upside ($185.43 - $165.35) / $165.35 = 12.1% $10.23 × 18x P/E

Adjust Assumptions

P/E Multiple

16.0x

Adjusted EPS

10.23$

Key Value Driver

Normalized P/E multiple (16x base case)

Implied Market Multiple 16.2x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $167.50 from 37 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $164.83 per share.

Warnings

⚠ The company's reported profits differ from official accounting profits by 62%. Check what costs are being left out of the adjusted number.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples